48 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
an orphan drug designation from the EMA.
To achieve the above goals, XORTX will continue to pursue non-dilutive and dilutive funding and expand
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
and regulatory progress, establishing the foundation for the Company’s 2024 goals. Key milestones include: 1/ the grant of U.S. ODD for the XRx-008 program … . Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
.
To achieve the above goals, XORTX will continue to pursue non-dilutive and dilutive funding and expand discussions to partner with major pharma / biotech
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
an orphan drug designation from the EMA.
To achieve the above goals, XORTX will continue to pursue non-dilutive and dilutive funding and expand
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
and regulatory progress, establishing the foundation for the Company’s 2024 goals. Key milestones include: 1/ the grant of U.S. ODD for the XRx-008 program … . Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of NDAs
424B3
e662x40 zypz2
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
idxhdnxb7vrdr281c ws
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
424B5
v9shrm8
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.2
o3j2xwjkmy2 ih
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
je9y0 n9okl7q
25 Aug 23
Prospectus supplement
6:00am
424B3
jnvqss
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.2
l2llf4ctuj0hb0k
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
11u6 6nx0vhlvjuk
14 Aug 23
Prospectus supplement
4:42pm
424B3
zilumg
14 Aug 23
Prospectus supplement
4:40pm
POS AM
gnhzswzr
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm
POS AM
s6mss 5fs
4 Aug 23
Prospectus update (post-effective amendment)
4:05pm
6-K
EX-99.2
1w6tgb4d a0
30 May 23
Notice of Annual & Special Meeting of Shareholders
7:00am
6-K
EX-99.2
94gej6w02 7zz3g
16 May 23
Condensed Interim Consolidated Financial Statements
9:32am